Study of orelabrutinib plus BR or G for untreated marginal zone lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of targeted therapy (orelabrutinib) plus chemotherapy (BR) or antibody therapy (G) for people with untreated marginal zone lymphoma. It aims to see if this combination can help patients who haven't had treatment yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of marginal zone lymphoma (MALT, SMZL, or NMZL).
- Your lymphoma has gotten worse, come back after local treatment, or local treatments aren't right for you.
- You need to have symptoms or signs that require treatment, like fevers, low blood counts, bleeding, or a fast-growing tumor.
- Your overall health (ECOG score) can be 0 to 3, but if it's 3, your doctor must think it's mainly due to the lymphoma.
- Your blood counts and liver/kidney function must be within acceptable ranges, with some flexibility if the lymphoma affects your bone marrow.
- You must be at least 18 years old and have a life expectancy of at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (orelabrutinib and obinutuzumab) as a first treatment for marginal zone lymphoma that has returned or progressed after local therapy. The goal is to see if this combination works better than current options.
This trial tests a combination of two targeted therapies—oralebrutinib (a pill that blocks a protein in cancer cells) and rituximab (an antibody infusion)—for people with marginal zone lymphoma that has returned or cannot be treated with local therapies. The goal is to see if this combo works well and is safe.
This trial tests a combination of two targeted drugs, orelabrutinib and obinutuzumab, for people with a type of slow-growing lymphoma called marginal zone lymphoma who have not had any previous treatment. The goal is to see if this combination can shrink or control the cancer with manageable side effects.
This trial tests an oral targeted therapy (orelabrutinib) for people with early-stage marginal zone lymphoma who have not yet had treatment. The goal is to see if this medication can control the cancer with fewer side effects than standard treatments.
This study tests a combination of three drugs—orelabrutinib, obinutuzumab, and lenalidomide—as a first treatment for marginal zone lymphoma. The goal is to see if this mix of targeted therapies works well and safely.
This trial tests a combination of two targeted drugs, orelabrutinib and rituximab, as the first systemic treatment for marginal zone lymphoma. If you have not yet had chemotherapy for your lymphoma and meet certain health criteria, you may be able to join.
Hear when a new Marginal Zone Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.